Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

M. Lesokhin, Alexander; H. Tomasson, Michael; Arnulf, Bertrand; J. Bahlis, Nizar; Miles Prince, H.; Niesvizky, Rubén; Rodríguez‐Otero, Paula; Martínez‐López, Joaquín; Koehne, Guenther; Touzeau, Cyrille; Jethava, Yogesh; Quach, Hang; Depaus, Julien; Yokoyama, Hisayuki; Eli Gabayan, Afshin; A. Stevens, Don; K. Nooka, Ajay; Manier, Salomon; Raje, Noopur; Iida, Shinsuke; S. Raab, Marc; Searle, Emma; Leip, Eric; T. Sullivan, Sharon; Conte, Umberto; Elmeliegy, Mohamed; Czibere, Akos; Viqueira, Andrea; Mohty, Mohamad

doi:10.1038/s41591-023-02528-9

Public

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Published in Nature Medicine • Aug 15, 2023

Authors:

Alexander M. Lesokhin

Michael H. Tomasson

Bertrand Arnulf

Abstract

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders...

Subject

Medicine

Neutropenia

Dosing

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!